ABSTRACT Purpose Secondary findings (SFs) are present in 1–4% of individuals
undergoing genome/exome sequencing. A review of how SFs are disclosed and what …

Purpose Clinical sequencing emerging in health care may result in secondary findings
(SFs). Methods Seventy-four of 6240 (1.2%) participants who underwent genome or exome …

The application of whole genome/exome sequencing technologies in clinical genetics and
research has resulted in the discovery of incidental findings unrelated to the primary …

Background Clinical interpretation of genetic variants in the context of the patient's
phenotype is becoming the largest component of cost and time expenditure for genome …

Limited translational genomic research data have been reported on the application of
exome sequencing and parallel gene testing for preconception carrier screening (PCS) …

Unsolicited findings (UFs) are uncovered unintentionally and predispose to a disease
unrelated to the clinical question. The frequency and nature of UFs uncovered in clinical …

Clinical genomic sequencing can identify pathogenic variants unrelated to the initial clinical
question, but of medical relevance to the patients and their families. With ongoing …

Background: The desire of parents to obtain a genetic diagnosis for their child with
intellectual disability and associated symptoms has long been framed as a diagnostic …

Background Family history has traditionally been an essential part of clinical care to assess
health risks. However, declining sequencing costs have precipitated a shift towards …

The increasing use of genomic sequencing in research means secondary findings (SF) is
more frequently detected and becoming a more pressing issue for researchers. This is …